UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Open public recruiting
Unique ID issued by UMIN UMIN000016805
Receipt No. R000019503
Scientific Title Tadalafil monotherapy versus tadalafil and solifenacin combined therapy for patients with lower urinary tract symptoms suggestive of benign prostate hyperplasia and overactive bladder: randomized controlled trial
Date of disclosure of the study information 2015/03/15
Last modified on 2015/09/24

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Tadalafil monotherapy versus tadalafil and solifenacin combined therapy for patients with lower urinary tract symptoms suggestive of benign prostate hyperplasia and overactive bladder: randomized controlled trial
Acronym Tadalafil monotherapy versus tadalafil and solifenacin combined therapy for benign prostate hyperplasia with overactive bladder
Scientific Title Tadalafil monotherapy versus tadalafil and solifenacin combined therapy for patients with lower urinary tract symptoms suggestive of benign prostate hyperplasia and overactive bladder: randomized controlled trial
Scientific Title:Acronym Tadalafil monotherapy versus tadalafil and solifenacin combined therapy for benign prostate hyperplasia with overactive bladder
Region
Japan

Condition
Condition benign prostate hyperplasia with overactive bladder
Classification by specialty
Urology
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To compare the efficacy for tadalafil monotherapy with tadalafil and solifenacin combined therapy in patients with benign prostate hyperplasia and overactive bladder, and to evaluate the safety of the combined therapy
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Change from baseline to end point for mean number of micturitions per 24 hours
Key secondary outcomes

Base
Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Cluster
Blinding Open -no one is blinded
Control Active
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 2
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 tadalafil 5mg monotherapy (12 weeks)
Interventions/Control_2 tadalafil 5mg and solifenacin 5mg combined therapy (12 weeks)
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
45 years-old <=
Age-upper limit

Not applicable
Gender Male
Key inclusion criteria 1. male patients aged 45 or older
2. patients with lower urinary tract symptoms (IPSS: 13 points or more)
3. patients with overactive bladder (OABSS: Q3 2 points or more and total score 3 points or more)
4. patients with prostate volume 20mL or more
5. patients with informed consent
Key exclusion criteria 1. patients who developed urinary retention in the past 12 months
2. patients who had post voiding residual volume 100mL or more
3. patients strongly suspected of prostate cancer
4. patients with indwelling urethral catheter or intermittent self-catheterization
5. patients with acute urinary tract infection
6. patients with nocturnal polyuria
7. patients with daily urine volume over 3000mL
8. patients with mechanical abnormality of lower urinary tract (eg. urethral stricture, bladder tumor and bladder stone)
9. patients without desire to void
10. patients with pyloric, duodenal or intestinal obstruction
11. patients with angle-closure glaucoma
12. patients with myasthenia gravis
13. patients with severe heart disease, renal dysfunction or liver dysfunction
14. patients with severe constipation
15. patients tadalafil and solifenacin is contraindicated
16. patients who have been determined to be unsuitable as a subject by a physician
Target sample size 200

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Mitsuhiro Tambo
Organization Kyorin University School of Medicine
Division name Department of Urology
Zip code
Address 6-20-2, Shinkawa, MIitaka, Tokyo
TEL 0422-47-5511
Email tanbodes@ks.kyorin-u.ac.jp

Public contact
Name of contact person
1st name
Middle name
Last name Mitsuhiro Tambo
Organization Kyorin University School of Medicine
Division name Department of Urology
Zip code
Address 6-20-2, Shinkawa, MIitaka, Tokyo
TEL 0422-47-5511
Homepage URL
Email tanbodes@ks.kyorin-u.ac.jp

Sponsor
Institute Department of Urology, Kyorin University School of Medicine
Institute
Department

Funding Source
Organization Department of Urology, Kyorin University School of Medicine
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2015 Year 03 Month 15 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Open public recruiting
Date of protocol fixation
2015 Year 02 Month 09 Day
Date of IRB
Anticipated trial start date
2015 Year 03 Month 01 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2015 Year 03 Month 15 Day
Last modified on
2015 Year 09 Month 24 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000019503

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.